Latest NewsNov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases All Filter By: Year2024202320222021202020192018201720162015Jun 11, 2021HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer ImmunotherapyMay 11, 2021HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal AntibodyApr 12, 2021Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibodyApr 12, 2021HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancersApr 12, 2021Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer< 1 … 6 7 8 9 10 … 17 >
